Medtech companies urge US FDA to enhance, not replace, 510(k) process
This article was originally published in SRA
US medtech industry association AdvaMed has reiterated its concerns over a report by the Institute of Medicine earlier this year that urged the Food and Drug Administration to replace its 510(k) review programme for clearing low- and medium-risk devices with a completely new regulatory process1,2.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.